Interim Results From the CATNON Trial Demonstrate Survival Benefit With Adjuvant Temozolomide for 1p/19q Non–Co-Deleted Anaplastic Glioma.

This randomized, open-label, phase III study was designed to evaluate the effect of temozolomide in newly diagnosed 1p/19q non–co-deleted anaplastic gliomas. Patients were randomized to receive radiotherapy alone or with adjuvant temozolomide, or to receive concurrent radiotherapy and temozolomide with or without adjuvant temozolomide. Adjuvant temozolomide was associated with a significant survival benefit.

The study supports the approach of surgery followed by radiotherapy and adjuvant temozolomide in patients with 1p/19q non–co-deleted anaplastic gliomas.

http://www.practiceupdate.com/c/56799/1/1/?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NjI5MDUyOTgwNDYS1&lid=10332481